Trending...
- The Evolution of the BDCV Platform: Empowering Mental Health & Wellness
- Postmortem Pathology Offers Expert Autopsy Services with Dignity and Accuracy
- Meet &insurance: The New Amenity Platform
PHILADELPHIA, Aug. 1, 2025 /PRNewswire/ -- Berger Montague PC, a Philadelphia-based law firm focused on investor protection, is investigating claims against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company") for potential violations of federal securities laws. A class action has been filed over allegations that the Company concealed safety concerns tied to its RP-A501 trial, leading to steep investor losses.
Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, where it operates its research and clinical programs in genetic medicine.
According to the complaint, the Company introduced a new immunomodulatory agent into the RP-A501 protocol, information that was not disclosed to shareholders before a patient suffered a fatal adverse event. The Company later announced an FDA clinical hold, triggering a nearly 37% stock price decline over two trading days.
More on The PennZone
Individuals who purchased Rocket Pharmaceuticals securities during the Class Period from September 17, 2024 through May 26, 2025, may be eligible to join the class action. The deadline to file for lead plaintiff is August 11, 2025. To learn more about your rights, CLICK HERE.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]
SOURCE Berger Montague
Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, where it operates its research and clinical programs in genetic medicine.
According to the complaint, the Company introduced a new immunomodulatory agent into the RP-A501 protocol, information that was not disclosed to shareholders before a patient suffered a fatal adverse event. The Company later announced an FDA clinical hold, triggering a nearly 37% stock price decline over two trading days.
More on The PennZone
- purelyIV Launches Niagen® IV Therapy – A Breakthrough in NAD+ Cellular Wellness
- Jewellok Unveils Cutting-Edge Specialty Gas Changeover Manifolds to Revolutionize Industrial and Medical Gas Delivery
- Press Snooze on Summer: 8 Inns Team Up to Help Guests Sleep In
- On the 30th anniversary of the Netscape IPO the inventor of the banner ad warns: "Trouble ahead."
- Early Bird Registration Now Open for the Inaugural OpenSSL Conference 2025
Individuals who purchased Rocket Pharmaceuticals securities during the Class Period from September 17, 2024 through May 26, 2025, may be eligible to join the class action. The deadline to file for lead plaintiff is August 11, 2025. To learn more about your rights, CLICK HERE.
About Berger Montague
Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
[email protected]
Caitlin Adorni
Berger Montague
(267) 764-4865
[email protected]
SOURCE Berger Montague
Filed Under: Business
0 Comments
Latest on The PennZone
- 123Invent Inventor Develops Newly Designed Head Covering
- 123Invent Inventor Develops New Appliance Power Saver (BDH-1037)
- DT Digital Relaunches as Redouble Digital, Expanding from Freelance Operation to Full-Service E-commerce Marketing Agency
- TL International Group Ltd Terminates Franchise Agreement with Apollo Rent A Car
- TSWHZC Addresses Recent Malicious Reports and Reaffirms Commitment to Regulatory Compliance and User Protection
- Introducing Lick Scented Bath Oils: Transform Your Bath into a Luxurious Escape
- Free Printable Math Bingo Cards Released for Teachers, Parents, and Students
- Dilworth Paxson LLP Welcomes New Partner, Lauren Sheller Insana
- Voices Across the Men's Health Network:
- Bent Danholm To Be Featured On Global Podcast Network In Live Interview
- AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
- Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
- David L. Lawrence Convention Center Selects showNets for 3-Year Internet & Wi-Fi Network Management Partnership
- Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
- YPTC Wins #1 Best Place to Work in Philadelphia
- Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
- Leading Retirement Expert Michael J. Seibert Featured on CNBC
- Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
- RCKT DEADLINE REMINDER: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Important Class Action Lawsuit Deadline
- Exeter Smiles in Allentown Enhances Orthodontic Precision with DIBS AI Technology